Antibody therapy for chronic lymphocytic leukemia: A promising new modality

Hematology/Oncology Clinics of North America

Volumn 18, Issue 4, 2004, Pages 895-913

  Lin, Thomas S ^a   Moran, Mollie ^a   Lucas, Margaret ^a   Waymer, Sharon ^a   Jefferson, Sara ^a   Fischer, Diane B ^a   Grever, Michael R ^a   Byrd, John C ^a  

^a Division of Surgical Oncology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CALCIUM CHANNEL; CD20 ANTIGEN; CD52 ANTIGEN; CYCLOPHOSPHAMIDE; FLUDARABINE; RITUXIMAB;

CANCER STAGING; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DRUG ACTIVITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DYSPNEA; GENE DELETION; GENE EXPRESSION; GENE MUTATION; HUMAN; HYPOTENSION; HYPOXEMIA; IMMUNOPHENOTYPING; IMMUNOSUPPRESSIVE TREATMENT; INFECTIOUS COMPLICATION; KARYOTYPE; LYMPHATIC LEUKEMIA; LYMPHOCYTOPENIA; NEUTROPENIA; PRIORITY JOURNAL; REVIEW; SEX RATIO; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TUMOR LYSIS SYNDROME;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; UNITED STATES;

EID: 4344691429     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2004.04.008     Document Type: Review

References (98)

1. Jemal A., Thomas A., Murray T., Thun M. Cancer statistics, 2002. CA Cancer J Clin. 52:2002;23-47
2. Diehl L.F., Karnell L.H., Menck H.R. The American College of Surgeons Commission on Cancer and the American Cancer Society. The National Cancer Data Base report on age, gender, treatment, and outcomes of patients with chronic lymphocytic leukemia. Cancer. 86:1999;2684-2692
3. Cheson B.D., Bennett J.M., Grever M., Kay N., Keating M.J., O'Brien S., et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 87:1996;4990-4997
4. Burger J.A., Tsukada N., Burger M., Zvaifler N.J., Dell'Aquila M., Kipps T.J. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood. 96:2000;2655-2663
5. Bannerji R., Byrd J.C. Update on the biology of chronic lymphocytic leukemia. Curr Opin Oncol. 12:2000;22-29
6. Binet J.L., Lepoprier M., Dighiero G., Charron D., D'Athis P., Vaugier G., et al. A clinical staging system for chronic lymphocytic leukemia: prognostic significance. Cancer. 40:1977;855-864
7. Rai K.R., Sawitsky A., Cronkite E.P., Chanana A.D., Levy R.N., Pasternack B.S. Clinical staging of chronic lymphocytic leukemia. Blood. 46:1975;219-234
8. Keating M.J., Kantarjian H., Talpaz M., Redman J., Koller C., Barlogie B., et al. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood. 74:1989;19-25
9. Grever M.R., Kopecky K.J., Coltman C.A., Files J.C., Greenberg B.R., Hutton J.J., et al. Fludarabine monophosphate: a potentially useful agent in chronic lymphocytic leukemia. Nouv Rev Fr Hematol. 30:1988;457-459
10. Johnson S., Smith A.G., Loffler H., Osby E., Juliusson G., Emmerich B., et al. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL. Lancet. 347:1996;1432-1438
11. Leporrier M., Chevret S., Cazin B., Boudjerra N., Feugier P., Desablens B., et al. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood. 98:2001;2319-2325
12. Rai K.R., Peterson B.L., Appelbaum F.R., Kolitz J., Elias L., Shepherd L., et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med. 343:2000;1750-1757
13. Bubien J.K., Zhou L.J., Bell P.D., Frizzell R.A., Tedder T.F. Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes. J Cell Biol. 121:1993;1121-1132
14. Leveille C., Al-Daccak R., Mourad W. CD20 is physically and functionally coupled to MHC class II and CD40 on human B cell lines. Eur J Immunol. 29:1999;65-74
15. Vose J.M., Giles F.J., Manshouri T., Bociek G., Bierman P.J., Armitage J.O., et al. High levels of soluble CD20 (sCD20) in patients with non-Hodgkin's lymphoma (NHL): correlation with clinical behavior and contrast with patients with Hodgkin's disease (HD). Blood. 98:2001;767a
16. Keating M.J., O'Brien S., Albitar M. Emerging information on the use of rituximab in chronic lymphocytic leukemia. Semin Oncol. 29(Suppl 2):2002;70-74
17. Manshouri T., Do K.A., Wang X., Giles F.J., O'Brien S.M., Saffer H.L., et al. Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood. 101:2003;2507-2513
18. Eisenbeis C.F., Caligiuri M.A., Byrd J.C. Rituximab: converging mechanisms of action in non-Hodgkin's lymphoma? Clin Cancer Res. 9:2003;5810-5812
19. Byrd J.C., Kitada S., Flinn I.W., Aron J.L., Pearson M., Lucas D., et al. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood. 99:2002;1038-1043
20. Pedersen I.M., Buhl A.M., Klausen P., Geisler C.H., Jurlander J. The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase- dependent mechanism. Blood. 99:2002;1314-1319
21. Farag S.S., Flinn I.W., Modali R., Lehman T.A., Young D., Byrd J.C. Fc gamma RIIIa and Fc gamma RIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia. Blood. 103:2004;1472-1474
22. Bannerji R., Kitada S., Flinn I.W., Pearson M., Young D., Reed J.C., et al. Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance. J Clin Oncol. 21:2003;1466-1471
23. McLaughlin P., Grillo-Lopez A.J., Link B.K., Levy R., Czuczman M.S., Williams M.E., et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 16:1998;2825-2833
24. Nguyen D.T., Amess J.A., Doughty H., Hendry L., Diamond L.W. IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients. Eur J Haematol. 62:1999;76-82
25. Winkler U., Jensen M., Manzke O., Schulz H., Diehl V., Engert A. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood. 94:1999;2217-2224
26. Huhn D., von Schilling C., Wilhelm M., Ho A.D., Hallek M., Kuse R., et al. Group GCLLS Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood. 98:2001;1326-1331
27. Itala M., Geisler C.H., Kimby E., Juvonen E., Tjonnfjord G., Karlsson K., et al. Standard-dose anti-CD20 antibody rituximab has efficacy in chronic lymphocytic leukaemia: results from a Nordic multicentre study. Eur J Haematol. 69:2002;129-134
28. Hainsworth J.D., Litchy S., Barton J.H., Houston G.A., Hermann R.C., Bradof J.E., et al. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol. 21:2003;1746-1751
29. Thomas D.A., O'Brien S., Giles F.J., Cortes J., Faderl S., Kantarjian H., et al. Single agent rituxan in early stage chronic lymphocytic leukemia (CLL). Blood. 98:2001;364a
30. Ginaldi L., De Martinis M., Matutes E., Farahat N., Morilla R., Catovsky D. Levels of expression of CD19 and CD20 in chronic B cell leukaemias. J Clin Pathol. 51:1998;364-369
31. Perz J., Topaly J., Fruehauf S., Hensel M., Ho A.D. Level of CD20 expression and efficacy of rituximab treatment in patients with resistant or relapsing B-cell prolymphocytic leukemia and B-cell chronic lymphocytic leukemia. Leuk Lymphoma. 43:2002;149-151
32. Berinstein N.L., Grillo-Lopez A.J., White C.A., Bence-Bruckler I., Maloney D., Czuczman M.S., et al. Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol. 9:1998;995-1001
33. Keating M.J., O'Brien S. High-dose rituximab therapy in chronic lymphocytic leukemia. Semin Oncol. 27(Suppl 12):2000;86-90
34. O'Brien S.M., Kantarjian H., Thomas D.A., Giles F.J., Freireich E.J., Cortes J., et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol. 19:2001;2165-2170
35. Byrd J.C., Murphy T., Howard R.S., Lucas M.S., Goodrich A., Park K., et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol. 19:2001;2153-2164
36. Byrd J.C., Waselenko J.K., Maneatis T.J., Murphy T., Ward F.T., Monahan B.P., et al. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. J Clin Oncol. 17:1999;791-795
37. Jensen M., Winkler U., Manzke O., Diehl V., Engert A. Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab). Ann Hematol. 77:1998;89-91
38. Lin T.S. L.M., Byrd J.C. Rituximab herapy for CLL. Semin Oncol. 30(4):2003;483-492
39. Byrd J.C., Peterson B.L., Morrison V.A., Park K., Jacobson R., Hoke E., et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood. 101:2003;6-14
40. Keating M.J., O'Brien S., Lerner S., Giles F.J., Andreeff M., Cortes J., et al. Combination chemo-antibody therapy with fludarabine (F), cyclophosphamide (C) and rituximab (R) achieves a high CR rate in previously untreated chronic lymphocytic leukemia (CLL). Blood. 96:2000;514a
41. Schulz H., Klein S.K., Rehwald U., Reiser M., Hinke A., Knauf W.U., et al. Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood. 100:2002;3115-3120
42. Schulz H., Klein S.K., Rehwald U., Reiser M., Hinke A., Knauf W.U., et al. Group GCS Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood. 100:2002;3115-3120
43. Keating M.J., O'Brien S., Lerner S., Wierda W., Kantarjian H. Chemoimmunotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) improves complete response (CR), remission duration and survival as initial therapy of chronic lymphocytic leukemia (CLL). J Clin Oncol. 22(14S):2004;573
44. Chevallier P., Penther D., Avet-Loiseau H., Robillard N., Ifrah N., Mahe B., et al. CD38 expression and secondary 17p deletion are important prognostic factors in chronic lymphocytic leukaemia. Br J Haematol. 116:2002;142-150
45. Dohner H., Fischer K., Bentz M., Hansen K., Benner A., Cabot G., et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood. 85:1995;1580-1589
46. Finn W.G., Kay N.E., Kroft S.H., Church S., Peterson L.C. Secondary abnormalities of chromosome 6q in B-cell chronic lymphocytic leukemia: a sequential study of karyotypic instability in 51 patients. Am J Hematol. 59:1998;223-229
47. Oscier D.G., Stevens J., Hamblin T.J., Pickering R.M., Lambert R., Fitchett M. Correlation of chromosome abnormalities with laboratory features and clinical course in B-cell chronic lymphocytic leukaemia. Br J Haematol. 76:1990;352-358
48. Jelinek D.F., Tschumper R.C., Geyer S.M., Bone N.D., Dewald G.W., Hanson C.A., et al. Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia. Br J Haematol. 115:2001;854-861
49. el Rouby S., Thomas A., Costin D., Rosenberg C.R., Potmesil M., Silber R., et al. p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood. 82:1993;3452-3459
50. Cordone I., Masi S., Mauro F.R., Soddu S., Morsilli O., Valentini T., et al. p53 expression in B-cell chronic lymphocytic leukemia: a marker of disease progression and poor prognosis. Blood. 91:1998;4342-4349
51. Wattel E., Preudhomme C., Hecquet B., Vanrumbeke M., Quesnel B., Dervite I., et al. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood. 84:1994;3148-3157
52. Kitada S., Andersen J., Akar S., Zapata J.M., Takayama S., Krajewski S., et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with In vitro and In vivo chemoresponses. Blood. 91:1998;3379-3389
53. Pettitt A.R., Sherrington P.D., Stewart G., Cawley J.C., Taylor A.M., Stankovic T. p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation. Blood. 98:2001;814-822
54. Stankovic T., Weber P., Stewart G., Bedenham T., Murray J., Byrd P.J., et al. Inactivation of ataxia telangiectasia mutated gene in B-cell chronic lymphocytic leukaemia. Lancet. 353:1999;26-29
55. Stankovic T., Stewart G.S., Fegan C., Biggs P., Last J., Byrd P.J., et al. Ataxia telangiectasia mutated-deficient B-cell chronic lymphocytic leukemia occurs in pregerminal center cells and results in defective damage response and unrepaired chromosome damage. Blood. 99:2002;300-309
56. Genini D., Budihardjo I., Plunkett W., Wang X., Carrera C.J., Cottam H.B., et al. Nucleotide requirements for the in vitro activation of the apoptosis protein-activating factor-1-mediated caspase pathway. J Biol Chem. 275:2000;29-34
57. Genini D., Adachi S., Chao Q., Rose D.W., Carrera C.J., Cottam H.B., et al. Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria. Blood. 96:2000;3537-3543
58. Byrd J., Smith L., Hackbarth M., Flinn I., Young D., Proffitt J., et al. Interphase cytogenetic abnormalities in chronic lymphocytic leukemia may predict response to rituximab. Cancer Res. 63:2003;36-38
59. Flynn J.M., Byrd J.C. Campath-1H monoclonal antibody therapy. Curr Opin Oncol. 12:2000;574-581
60. Hale G., Bright S., Chumbley G., Hoang T., Metcalf D., Munro A.J., et al. Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement. Blood. 62:1983;873-882
61. Hale G., Dyer M.J., Clark M.R., Phillips J.M., Marcus R., Riechmann L., et al. Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet. 2:1988;1394-1399
62. Treumann A., Lifely M.R., Schneider P., Ferguson M.A. Primary structure of CD52. J Biol Chem. 270:1995;6088-6099
63. Domagala A., Kurpisz M. CD52 antigen: a review. Med Sci Monit. 7:2001;325-331
64. Rowan W., Tite J., Topley P., Brett S.J. Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells. Immunology. 95:1998;427-436
65. Hale G., Swirsky D., Waldmann H., Chan L.C. Reactivity of rat monoclonal antibody CAMPATH-1 with human leukaemia cells and its possible application for autologous bone marrow transplantation. Br J Haematol. 60:1985;41-48
66. Salisbury J.R., Rapson N.T., Codd J.D., Rogers M.V., Nethersell A.B. Immunohistochemical analysis of CDw52 antigen expression in non-Hodgkin's lymphomas. J Clin Pathol. 47:1994;313-317
67. Bowen A.L., Zomas A., Emmett E., Matutes E., Dyer M.J., Catovsky D. Subcutaneous CAMPATH-1H in fludarabine-resistant/relapsed chronic lymphocytic and B-prolymphocytic leukaemia. Br J Haematol. 96:1997;617-619
68. Keating M.J., Byrd J.C., Rai K., Flinn I., Jain V., Binet L., et al. Group C-Hcs Multicenter study of Campath-1H in patients with chronic lymphocytic leukemia (B-CLL) refractory to fludarabine. Blood. 96:2000;722a
69. Keating M.J., Flinn I., Jain V., Binet J.-L., Hillmen P., Byrd J.C., et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood. 99:2002;3554-3561
70. Osterborg A., Fassas A.S., Anagnostopoulos A., Dyer M.J., Catovsky D., Mellstedt H. Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia. Br J Haematol. 93:1996;151-153
71. Osterborg A., Dyer M.J., Bunjes D., Pangalis G.A., Bastion Y., Catovsky D., et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia: European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol. 15:1997;1567-1574
72. Rai K.R., Coutre S., Rizzieri D., Gribben J.G., Flinn I., Rabinowe S., et al. Group CS Efficacy and safety of alemtuzumab (Campath-1H) in refractory B-CLL patients treated on a compassionate basis. Blood. 98:2001;365a
73. Lundin J., Kimby E., Bjorkholm M., Broliden P.A., Celsing F., Hjalmar V., et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood. 100:2002;768-773
74. Dyer M.J., Kelsey S.M., Mackay H.J., Emmett E., Thornton P., Hale G., et al. In vivo 'purging' of residual disease in CLL with Campath-1H. Br J Haematol. 97:1997;669-672
75. Montillo M., Cafro A.M., Tedeschi A., Brando B., Oreste P., Veronese S., et al. Safety and efficacy of subcutaneous Campath-1H for treating residual disease in patients with chronic lymphocytic leukemia responding to fludarabine. Haematologica. 87:2002;695-700
76. Rai K.R., Peterson B., Larson R.A. A phase II trial of fludarabine followed by alemtuzumab (Campath-1H) in previously untreated chronic lymphocytic leukemia (CLL) Patients with Active Disease: Cancer and Leukemia Group B (CALGB) study 19901. Blood. 101:2002;205a
77. O'Brien S., Kantarjan H.M., Thomas D.A., Cortes J., Giles F.J., Wierda W.G., et al. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer. 98(12):2003;2657-2663
78. Wendtner C.M., Fingerle-Rowson G., Jaeger G., Campe H., Engert A., Doehner H., et al. High efficacy but considerable toxicity of campath-1H consolidation therapy in CLL patients responding to fludarabine: results of a randomized phase III trial. Proc Am Soc Clin Oncol. 2003
79. Khorana A., Bunn P., McLaughlin P., Vose J., Stewart C., Czuczman M.S. A phase II multicenter study of Campath-1H antibody in previously treated patients with nonbulky non-Hodgkin's lymphoma. Leuk Lymphoma. 41:2001;77-87
80. Tang S.C., Hewitt K., Reis M.D., Berinstein N.L. Immunosuppressive toxicity of CAMPATH1H monoclonal antibody in the treatment of patients with recurrent low grade lymphoma. Leuk Lymphoma. 24:1996;93-101
81. Lundin J., Osterborg A., Brittinger G., Crowther D., Dombret H., Engert A., et al. CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphoma: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma. J Clin Oncol. 16:1998;3257-3263
82. Brett S., Baxter G., Cooper H., Johnston J.M., Tite J., Rapson N. Repopulation of blood lymphocyte sub-populations in rheumatoid arthritis patients treated with the depleting humanized monoclonal antibody, CAMPATH-1H. Immunology. 88:1996;13-19
83. Condiotti R., Nagler A. Campath-1G impairs human natural killer (NK) cell-mediated cytotoxicity. Bone Marrow Transplant. 18:1996;713-720
84. Fabian I., Flidel O., Gadish M., Kletter Y., Slavin S., Nagler A. Effects of CAMPATH-1 antibodies on the functional activity of monocytes and polymorphonuclear neutrophils. Exp Hematol. 21:1993;1522-1527
85. Buggins A.G.S., Mufti G.J., Fishlock K., Arno M., Hale G., Waldmann H., et al. Peripheral blood dendritic cells express CD52 and are depleted in vivo by treatment with Campath-1H. Blood. 98:2001;366a
86. Hale G., Zhang M.J., Bunjes D., Prentice H.G., Spence D., Horowitz M.M., et al. Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection. Blood. 92:1998;4581-4590
87. Hale G., Jacobs P., Wood L., Fibbe W.E., Barge R., Novitzky N., et al. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells. Bone Marrow Transplant. 26:2000;69-76
88. Flinn I.W., Sickler J., Lucas M., Buj V., Waymer S., Shinn C., et al. Randomized trial of early versus delayed GM-CSF with Campath-1H: preliminary feasibility and correlative biologic studies results. Blood. 96:2000;838a
89. Lin T.S., Flinn I.W., Lucas M.S., Sickler J., Moran M., Porcu P., et al. Filgrastim and alemtuzumab (Campath-1H) for refractory chronic lymphocytic leukemia: high frequency of cytomegalovirus disease and delayed neutropenia. Blood. 100:2002;802a
90. Kennedy B., Rawstron A., Carter C., Ryan M., Speed K., Lucas G., et al. Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. Blood. 99:2002;2245-2247
91. Nabhan C., Tallman M.S., Riley M.B., Fitzpatrick J., Gordon L.I., Gartenhaus R., et al. Phase I study of rituximab and Campath-1H in patients with relapsed or refractory chronic lymphocytic leukemia. Blood. 98:2003;365a
92. Faderl S., Thomas D.A., O'Brien S., Garcia-Manero G., Kantarjian H.M., Giles F.J., et al. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood. 101:2003;3413-3415
93. Lin K., Sherrington P.D., Dennis M., Matrai Z., Cawley J.C., Pettitt A.R. Relationship between p53 dysfunction, CD38 expression, and IgV(H) mutation in chronic lymphocytic leukemia. Blood. 100:2002;1404-1409
94. Stilgenbauer S. Genomic aberrations, p53 abnormalities, and IgV mutation: relationship to disease evolution, resistance to therapy, and clinical course of CLL. Leuk Lymphoma. 62(2):2000;76-82
95. Sturm I., Bosanquet A.G., Hermann S., Guner D., Dorken B., Daniel P.T. Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy. Cell Death Differ. 10:2003;477-484
96. Byrd J.C., Smith L., Hackbarth M.L., Flinn I.W., Young D., Proffitt J.H., et al. Interphase cytogenetic abnormalities in chronic lymphocytic leukemia may predict response to rituximab. Cancer Res. 63:2003;36-38
97. Stilgenbauer S., Dohner H. Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. N Engl J Med. 347:2002;452-453
98. Lozanski G., Heerema N.A., Flinn I.W., Smith L., Harbison J., Webb J., et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood. 103:2004;3278-3281